What is the clinical evidence to support off-label rapamycin therapy in healthy adults?

Kraig et al.’s results reported no significant improvement in various metabolic parameters, while noting several potentially undesirable findings between groups, including a significant decrease in plasma albumin, increased triglycerides and Hemoglobin A1C (HbA1C) and a near-significant (p=0.06) increase for very-low-density lipoprotein (VLDL) within rapamycin-treated subjects.

also in 959 other papers

The latter consideration may be significant because the effect of mTOR inhibition was greatest in subjects >85y, and in subjects >65y with evidence of asthma, when compared with cohort controls.

also in 4,300 other papers